Baxter Healthcare
As of the edition of 20 October 2026, Baxter Healthcare runs 128 drugs, 128 of them marketed; it is on route A at 0 targets and on route B at 23 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 128 |
| Total | 128 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cyclophosphamide anhydrous | none listed | 0 |
| Doxorubicin | none listed | 3 |
| Dexmedetomidine | none listed | 9 |
| Bupivacaine | none listed | 1 |
| Lidocaine | none listed | 2 |
| Acetaminophen | none listed | 17 |
| Ketamine | none listed | 10 |
| Midazolam | none listed | 1 |
| Propofol | none listed | 0 |
| Cholecalciferol | none listed | 2 |
| Tranexamic acid | none listed | 2 |
| Insulin human | Ended 1994 (computed from the first US licence) | 1 |
| Ifosfamide | none listed | 0 |
| Sodium chloride | none listed | 0 |
| Bendamustine | Ends 2029 (patent) | 0 |
| Sevoflurane | none listed | 12 |
| Epinephrine | none listed | 23 |
| Ondansetron | none listed | 0 |
| Metronidazole | none listed | 0 |
| Magnesium sulfate anhydrous | none listed | 0 |
| Propranolol | none listed | 4 |
| Chlorhexidine | none listed | 0 |
| Vancomycin | none listed | 0 |
| Folic acid | none listed | 0 |
| Ascorbic acid | none listed | 0 |
A route B row is one company at one target. 103 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 0 targets, route B at 23 targets.
All 23 rows on route A or B
In the product23 company-target rows on route A or B; 20 are not shown here, and no score is.
See all 23 targets where Baxter Healthcare needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.